Table 1.
New JHR score: major and minor criteria according to the clinical status, LEPJAR-NC study, New Caledonia, 2021–2024.
Table 2.
categorization of the JHR status, LEPJAR-NC study, New Caledonia, 2021–2024.
Fig 1.
Flow diagram of patient inclusion, antibiotic treatment, and occurrence of Jarisch–Herxheimer reaction (JHR) among 81 laboratory-confirmed leptospirosis cases in New Caledonia.
Table 3.
Socio-demographic description and risk factors of the enrolled patients, LEPJAR-NC study, New Caledonia, December 2021–Mai 2024.
Table 4.
Description of the biological results at admission of the enrolled patients with confirmed leptospirosis, LEPJAR-NC study, New Caledonia, 2021–2024.
Table 5.
Evolution of the CRP and the cytokines between H0 (admission), H3 and H6, LEPJAR-NC study, New Caledonia, 2021–2024.
Table 6.
Description of the socio-demographic parameters according to JHR, LEPJAR-NC study, New Caledonia, 2021–2024.
Table 7.
Description of the biological parameters according to JHR status, LEPJAR-NC study, New Caledonia, 2021-2024.
Table 8.
Median of difference between H3 and H0, and H6 and H3 for the different inflammatory parameters according to JHR status, LEPJAR-NC study, New Caledonia, 2021–2024.